GlobeImmune sets IPO price range in $75m fundraising effort
This article was originally published in Scrip
With its cash balance waning, GlobeImmune has set early pricing parameters for its initial public offering at $11 to $13 per share for five million shares of common stock, which will gross $55-65 million for the Louisville, Colorado-based company's mid-stage oncology drug candidate optioned by Celgene and early-stage hepatitis B virus (HBV) asset licensed to Gilead Sciences.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.